-

Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2021 after the close of market on Monday, February 28, 2022. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://protect-us.mimecast.com/s/IyUzCADA4pUjMMGcmQqy2. A webcast replay will be available following conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call can be accessed as follows:

U.S./Canada participant dial-in number (toll-free):

 

(855) 541-0980

International participant dial-in number:

 

(970) 315-0440

Conference I.D.:

 

5377945

About Veracyte

Veracyte, Inc. (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Contacts

Tracy Morris
Vice President of Corporate Communications & Investor Relations
tracy.morris@veracyte.com
650-380-4413

Industry:

Veracyte, Inc.

NASDAQ:VCYT
Release Summary
Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
Release Versions
English

Contacts

Tracy Morris
Vice President of Corporate Communications & Investor Relations
tracy.morris@veracyte.com
650-380-4413

More News From Veracyte, Inc.

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal i...

OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer...

Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Growth Stock Conference – Chicago, IL Presentation on Tuesday, June 2nd at 2:00 p.m. Central Time 2026 Jefferies Global Healthcare Conference – New York, NY Fireside chat on Thursday, June 4th at 8:10 a.m. Eastern Time Live audio webcasts of the company’s presentations will be available by visiting Ver...
Back to Newsroom